FDA approves 6 week dosing for pembrolizumab for all approved adult indications

In US, dosage of 400 mg every six weeks, including as a monotherapy and in combination treatments, has been approved, in addition to the current dose of 200 mg every three weeks. In UK, the 6-weekly regimen is currently only licensed for use as monotherapy.


Biospace Inc.